About Gout Therapeutics
Gout is a form of arthritis which can be intensely painful and it is caused by having sodium urate crystals in joints. The approval of febuxostat, a non-purine-analogue inhibitor of xanthine oxidase, by the European Medicines Agency and the US Food and Drug Administration heralds a new era in the treatment of gout. Surging adoption of these biologics because of their ability to produce powerful anti-inflammatory action is likely to drive the market during the forecast period.
|High Growth Market||Asia Pacific|
|Unit||Value (USD Billion)|
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Gout Therapeutics market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
Regeneron Pharmaceuticals (United States), CymaBay Therapeutics (United States), LG Life Sciences (South Korea), Eisai Co., Ltd. (Japan), Antares Pharma (United States), Boehringer Ingelheim (Germany), AstraZeneca (United Kingdom), Takeda Pharmaceuticals (Japan), GlaxoSmithKline (United Kingdom), Eli Lilly (United States), Merck & Co. (United States) and Novartis (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Teijin Pharma (Japan), JW Pharmaceutical (South Korea), Vertex Pharmaceuticals (United States) and Astellas Pharma (Japan).
AMA Research has segmented the market of Global Gout Therapeutics market by Type (NSAIDs, Corticosteroids, Colchicine and Urate-Lowering Agents), Application (Hospitals and Clinics) and Region.
On the basis of geography, the market of Gout Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2021. If we see Market by Diseases Type, the sub-segment i.e. Acute Gout will boost the Gout Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Leaders and their expansionary development strategies
On 20 April 2022, Regeneron Pharmaceuticals has entered a definitive agreement to acquire all outstanding shares of clinical stage biopharmaceutical company Checkmate Pharmaceuticals The Checkmate takeover is anticipated to bolster Regeneronís portfolio of varied and combinable immuno-oncology candidates.
On 30 December 2020, The FDA has approved lesinurad (Zurampic) to be used in combination with allopurinol (Zyloprim) or febuxostat (Uloric) for the treatment of hyperuricemia associated with gout. Lesiunard is the first in a new class of drugs called selective uric acid reabsorption inhibitors (SURIs) to be approved in the United States.
- Increasing Adoption of Newer Therapies
- Surging Number of Geriatric Population Across the World
- Increased in Incidence and Prevalence of Gout in Developed Economies
- Increasing Adoption of Biologics
- Lack of Awareness in Developing Economies
- Increased Drug Resistance
- Side-Effects of the Prescribed Drugs
Key Target AudienceProviders of Gout Therapeutics, Potential Investors, Market Research Firms, Regulatory Bodies, End-Users and Others
About ApproachTo evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand companys positioning regarding market value, volume and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.